Related Experiment Videos
Patent ductus arteriosus in preterm neonates
R Aggarwal1, A Bajpai, A K Deorari
1Division of Neonatology, Department of Pediatrics, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India.
Indian Journal of Pediatrics
|January 5, 2002
Summary
Patent ductus arteriosus (PDA) in premature infants can cause pulmonary circulation overload. Early detection and management with indomethacin or fluid restriction are key, while term neonates require further cardiac investigation.
Area of Science:
- Neonatology
- Pediatric Cardiology
- Perinatal Medicine
Background:
- Patent ductus arteriosus (PDA) occurs when the ductus arteriosus fails to close postnatally, leading to pulmonary overcirculation.
- Premature neonates, especially those with respiratory distress syndrome, are at higher risk for PDA.
- Early indicators include respiratory status decline in ventilated neonates and metabolic acidosis.
Purpose of the Study:
- To summarize the key aspects of patent ductus arteriosus (PDA) in neonates.
- To highlight diagnostic indicators and management strategies for PDA.
- To differentiate management approaches for preterm versus term neonates.
Main Methods:
- Review of current medical management protocols for PDA.
- Discussion of diagnostic signs and indicators.
- Emphasis on pharmacological and fluid management strategies.
Main Results:
- Indomethacin remains the primary medical treatment for PDA in preterm neonates.
- Restricted fluid therapy shows potential in PDA prevention among preterm infants.
- PDA in term neonates necessitates investigation for congenital heart disease.
Conclusions:
- Prompt recognition and management of PDA are crucial for neonatal respiratory and circulatory health.
- Indomethacin and fluid management are vital in preterm PDA cases.
- Thorough cardiac evaluation is essential for term neonates diagnosed with PDA.